A randomized trial in Nature Aging found that four weeks of urolithin A shifted the immune profile of healthy middle-aged adults. It expanded naive-like CD8+ T cells and boosted their fat-burning capacity. But the headline number is small: a 0.5 percentage point change. The study ran only 4 weeks in 50 people, measured biomarkers rather than infections, and was funded by the maker of Mitopure. Here is what the data show, what they don't, and who might want to pay attention.
This page is available in